Chimerix traded at $1.80 this Wednesday February 8th, decreasing $0.02 or 1.10 percent since the previous trading session. Looking back, over the last four weeks, Chimerix lost 4.76 percent. Over the last 12 months, its price fell by 70.68 percent. Looking ahead, we forecast Chimerix to be priced at 1.76 by the end of this quarter and at 1.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Ardelyx 3.28 -0.07 -2.09% 319.44%
Chimerix 1.80 -0.02 -1.10% -70.68%
Curis 0.76 -0.004 -0.47% -78.56%
Dynavax Technologies 11.22 -0.37 -3.19% -14.22%
Emergent BioSolutions 13.25 -0.85 -6.03% -71.62%
Gilead Sciences 85.67 -0.38 -0.44% 35.17%
Glaxosmithkline 36.32 0.15 0.41% -17.94%
Life Technologies 2.38 -0.09 -3.64% -59.04%
Merck & Co 106.64 0.96 0.91% 39.29%
Mirati Therapeutics 50.52 -3.19 -5.94% -55.85%
Novavax 10.44 -0.45 -4.13% -88.63%
Xoma 20.50 -0.44 -2.10% 2.76%

Indexes Price Day Year
USND 11911 -203.27 -1.68% -17.80%
US2000 1943 -30.01 -1.52% -6.76%

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.